B+
Bull case
25%
Probability
Target price
$14.50
+61.1% vs current
KPTI
Karyopharm TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.50
-16.7% vs current
B-
Bear case
30%
Probability
Target price
$4.50
-50.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-03
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+39.8
Score
AI commentary
This remains a cautious monitoring memo, not an earnings-driven upgrade. On a scheduled T+3 follow-up for the April 30, 2026 earnings date, checked company sources showed no confirmed Q1 2026 earnings release or results filing through May 3, 2026, so revenue/EPS surprise, guidance revision and delayed analyst target-reset evidence are still unavailable. The May 1, 2026 anchor close of $8.77 sits above the March 24, 2026 private-placement price of $6.785, suggesting investors still assign value to upcoming data catalysts, but absent a confirmed post-print company update the deterministic prior remains the better guide and it is still negative across forward horizons.
RankAlpha Sentiment Codex - 2026-05-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-02eventJune 2, 2026 ASCO SENTRY presentation could sharpen the post-topline read on myelofibrosisHigh impact
On April 21, 2026, Karyopharm said the Phase 3 SENTRY myelofibrosis data were accepted for a late-breaking oral presentation at ASCO on June 2, 2026 [#PR-2026-04-21]. Because the topline outcome was mixed, the detailed presentation matters mainly for subgroup quality, durability and whether investors gain more confidence in a viable FDA discussion path rather than for a clean efficacy surprise.
2026-07-15catalystMid-2026 XPORT-EC-042 endometrial cancer readout remains the largest clean upside optionalityHigh impact
Karyopharm's February 12, 2026 year-end update said topline data from the event-driven Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer are expected in mid-2026 [#PR-2026-02-12]. This remains the most meaningful pipeline swing factor because a positive readout would reopen franchise expansion beyond the mixed SENTRY outcome, while a miss would further tighten strategic flexibility before the late-Q3 2026 runway boundary.
2026-09-30catalystLate-Q3 2026 liquidity deadline keeps financing or partnering pressure elevatedHigh impact
Karyopharm said in its March 27, 2026 8-K that existing liquidity, including cash, investments, product revenue and license revenue, funds current operating plans only into late Q3 2026 [#8-K-2026-03-27]. That means any delay in clinical de-risking or commercial underperformance can quickly push the company back toward dilution, debt amendments, partnering or other balance-sheet actions.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-03 • Updated nightlySource: Internal modelMethodology